Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()
DOP42: Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Sigall Boneh*1,2, J. Van Limbergen3, A. Assa4, R. Shaoul5, E. Wine6, P. Milman7, S. Cohen8, M. Kori9, S. Peleg10, A. On11, H. Shamaly12, L. Abramas1, A. Levine1,2

1Wolfson Medical Center, Pediatric Gastroenterology, Holon, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3Dalhousie University, Halifax, Canada, 4Schneider Hospital, Petach Tikva, Israel, 5Meyer Hospital, Haifa, Israel, 6University of Alberta, Edmonton, Canada, 7Hadassah Hospital, Jerusalem, Israel, 8Tel Aviv Medical Center, Tel Aviv, Israel, 9Kaplan Hospital, Rehovot, Israel, 10HaEmek Hospital, Afula, Israel, 11Poriah hospital, Tiberias, Israel, 12French Hospital, Nazareth, Israel

DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders

ECCO '19 Copenhagen

Year: 2019
Authors:

D. T. Rubin1, M. C. Dubinsky2, M. Lukas*3, D. Quirk4, C. I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, H. Fan4, D. A. Woodworth4, G. Chan4, C. Su4

1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA, 2Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, USA, 3Charles University, Prague, Czech Republic, 4Pfizer Inc., Collegeville, PA, USA

DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Rodriguez-Lago*1, J. Castro-Poceiro2, A. Fernández-Clotet2, F. Mesonero3, A. López-Sanromán3, A. López-García4, L. Márquez4, A. Clos-Parals5, F. Cañete5, M. Vicuña6, Ó. Nantes6, O. Merino7, V. Matallana Royo8, J. Gordillo9, A. Elorza1, R. Vicente10, M. J. Casanova11,12, R. Ferreiro-Iglesias13, P. Pérez-Galindo14, J. M. Benítez15,16, C. Taxonera17, M. J. García García18, E. Martín Arranz19, M. Calafat20, A. Martín-Cardona21,22, F. Muñoz Núñez23, J. O. Miquel-Cusachs24, E. Sáinz Arnau25, J. P. Gisbert11, Young IBD Group from GETECCU1

1Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 2Hospital Clinic, Gastroenterology, Barcelona, Spain, 3Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 4Hospital del March, Gastroenterology, Barcelona, Spain, 5Hospital Universitario Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 6Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 7Hospital de Cruces, Gastroenterology, Bilbao, Spain, 8Hospital Universitario Puerta de Hierro, Gastroenterology, Majadahonda, Spain, 9Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 10Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, 11Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 12Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 13Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain, 14Hospital Montecelo, Gastroenterology, Pontevedra, Spain, 15Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, 16IMIBIC, Córdoba, Spain, 17Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 18Hospital Marqués de Valdecilla, Gastroenterology, Santander, Spain, 19Hospital Universitario La Paz, Gastroenterology, Madrid, Spain, 20Hospital Son Llàtzer, Gastroenterology, Palma, Spain, 21Hospital Universitari Mutua Terrassa, Gastroenterology, Terrassa, Spain, 22Centro de Investigación biomédica en red de enfermedades hepáticas y digestivas (CIBERehd), Terrassa, Spain, 23Hospital de Salamanca, Gastroenterology, Salamanca, Spain, 24Hospital Universitario de Girona, Gastroenterology, Girona, Spain, 25Hospital Arnau de Vilanova, Gastroenterology, Lérida, Spain

DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Vande Casteele*1,2, K. Papamichael3, J. Jeyarajah2, M. T. Osterman4, A. S. Cheifetz3

1University of California San Diego, Department of Medicine, La Jolla, USA, 2Robarts Clinical Trials, Inc., London, Canada, 3Beth-Israel Deaconess Medical Center, Harvard Medical School, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Boston, USA, 4University of Pennsylvania, Department of Medicine, Perelman School of Medicine, Philadelphia, USA

DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1, M. Ferrante2, B. R. Bhandari3, E. Berliba4, T. Hibi5, G. Geert. R. D’Haens6, J. Tuttle7, K. Krueger8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9

1University California San Diego, La Jolla, California, USA, 2UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3Delta Research Partners, LLC, Bastrop, LA, USA, 4Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, 5Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, 6Amsterdam University Medical Centers, Amsterdam, The Netherlands, 7Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, USA, 8Eli Lilly and Company, Indianapolis, Indiana, USA, 9Western University, Robarts Clinical Trials Inc., London, Ontario, Canada

DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Van Assche*1, S. R. Targan2, T. Baker3, C. D. O’Brien3, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4,5, D. Rowbotham6,7, T. Hisamatsu8, S. Danese9, B. E. Sands10, L. Peyrin-Biroulet11

1University of Leuven, Leuven, Belgium, 2Cedars-Sinai Medical Center, Los Angeles, USA, 3Janssen Research and Development, Spring House, USA, 4Concord Hospital, Sydney, Australia, 5Macquarie University Hospital, Sydney, Australia, 6Auckland City Hospital, Auckland, New Zealand, 7University of Auckland, Auckland, New Zealand, 8Kyorin University, Tokyo, Japan, 9Humanitas Research Hospital, Milan, Italy, 10Icahn School of Medicine at Mount Sinai, New York, USA, 11Nancy University Hospital, Vandœuvre-lès-Nancy, France

DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. D’Haens*1, S. Danese2, M. Davies3, M. Watanabe4, T. Hibi5

1Academic Medical Centre, Amsterdam, The Netherlands, 2Humanitas Research Hospital, Gastroenterology, Milano, Italy, 3Mitsubishi Tanabe Europe Ltd., London, UK, 4Tokyo Medical and Dental University, Gastroenterology, Tokyo, Japan, 5University Kitasato Hospital, Gastroenterology, Tokyo, Japan

DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

1Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, USA, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l’Archet, Nice, France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, USA, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, USA, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, USA, 15Cytel Inc., Cambridge, MA, USA, 16University Hospitals Leuven, Leuven, Belgium

DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Peyrin-Biroulet*1, S. Danese2, E. Louis3, P. D. R. Higgins4, M. Dubinsky5, F. Cataldi6, Q. Zhou6, W-J. Lee6, K. Kligys6, A. P. Lacerda6

1University of Lorraine, Nancy, France, 2Istituto Clinico Humanitas, Milan, Italy, 3CHU de Liège et Université de Liège, Liège, Belgium, 4University of Michigan, Ann Arbor, USA, 5Icahn School of Medicine at Mount Sinai, New York, USA, 6AbbVie Inc., North Chicago, USA

DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

1Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, USA, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, USA, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, USA, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, USA, 15Cytel Inc., Cambridge, MA, USA, 16University Hospitals Leuven, Leuven, Belgium

DOP52: Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1, B. Sands2, T. Kobayashi3, J. Tuttle4, J. Schmitz5, M. Durante5, R. Higgs5, J. B. Canavan5, R. Siegel5, M. Ferrante6

1University California San Diego, La Jolla, California, USA, 2Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 3Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 4Eli Lilly and Company, Lilly Biotechnology Center, San Diego, CA, USA, 5Eli Lilly and Company, Indianapolis, IN, USA, 6UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

DOP53: Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Sandborn1, D. Nguyen2, B. Ferslew2, L-Y. Hao3, T. Kanno3, L. Tomsho3, D. Boyle1, R. Graham2, B. Abhyankar2, J. Panes*4

1University of California San Diego, Medicine, San Diego, USA, 2Theravance Biopharma US, Inc., South San Francisco, USA, 3Janssen R&D, Springhouse, USA, 4Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain

DOP54: Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Danese*1, B. E. Sands2, C. D. O'Brien3, H. Zhang3, J. Johanns3, S. Sloan3, J. Izanec4, P. Szapary3, C. Marano3, R. W. Leong5,6, D. Rowbotham7,8, S. R. Targan9, G. Van Assche10

1Humanitas Research Hospital, Milan, Italy, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Janssen Research & Development, LLC, Spring House, USA, 4Janssen Scientific Affairs, LLC, Horsham, USA, 5Concord Hospital, Sydney, Australia, 6Macquarie University Hospital, Sydney, Australia, 7Auckland City Hospital, Auckland, New Zealand, 8University of Auckland, Auckland, New Zealand, 9Cedars-Sinai Medical Center, Los Angeles, USA, 10University of Leuven, Leuven, Belgium

DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing

ECCO '19 Copenhagen

Year: 2019
Authors:

E. S. Jung*1,2, K-w. Choi3, S. W. Kim2, M. Hübenthal1, S. Mucha1, J. Park2, Z. Park3, D. Ellinghaus1, S. Schreiber1, A. Franke1, W. Y. Oh3, J. H. Cheon2

1Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany, 2Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea, 3National Institute of Food and Drug Safety Evaluation, Clinical Research Division, Cheongju, South Korea

DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Strik*1,2, S. Berends3, D. Mould4, R. Mathôt3, C. Ponsioen2, J. van den Brande5, J. Jansen6, D. Hoekman7, J. Brandse8, M. Löwenberg2, G. D'Haens2

1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Amsterdam UMC, location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3Amsterdam UMC, Location AMC, Hospital Pharmacy, Amsterdam, The Netherlands, 4Projections Research Inc., Phoenixville, USA, 5Tergooi Hospital, Blaricum, The Netherlands, 6Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 7Amsterdam UMC, location AMC, Clinical Genetics, Amsterdam, The Netherlands, 8Amsterdam UMC, location VuMc, Gastroenterology and Hepatology, Amsterdam, The Netherlands

DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST&UC

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Maaser*1, F. Petersen1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, D. Lang4, T. Kucharzik1

1University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany, 2Gastroenterology Practice, Oldenburg, Germany, 3Biostatistik Tuebingen, Tuebingen, Germany, 4AbbVie Deutschland GmbH & Co.KG, Medical Department Gastroenterology, Wiesbaden, Germany

DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

G. H. Huynh*1, M. W. Carroll1, A. M. Griffiths2, W. El-Matary3, A. Petrova4, C. Prosser5, C. Kluthe6, J. C. deBruyn7, D. Tomalty2, D. R. Mould8, E. Wine4, H. Q. Huynh4

1University of Alberta, Paediatrics, Edmonton, Canada, 2Hospital for Sick Children, University of Toronto, Paediatrics, Toronto, Canada, 3The Children's Hospital University of Manitoba, Paediatrics, Winnipeg, Canada, 4Stollery Children's Hospital University of Alberta, Paediatrics, Edmonton, Canada, 5Alberta Health Services, Biochemistry, Edmonton, Canada, 6Alberta Health Services, Paediatrics, Edmonton, Canada, 7Alberta Children's Hospital University of Calgary, Paediatrics and Community Health Sciences, Calgary, Canada, 8Projections Research, Phoenixville, USA

DOP59: Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Raimundo Fernandes*1, S. Bernardo1, C. Simões1, L. Correia1, P. Moura Santos1, A. Rita Gonçalves1, A. Valente1, C. Baldaia1, R. Tato Marinho1

1Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Gastrenterology and Hepatology Unit, Lisbon, Portugal

DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Pavlidis*1, A. Tsakmaki1, U. Niazi2, J. Digby-Bell1, G. Lombardi1, B. Hayee3, G. Bewick1, N. Powell1

1King's College London, London, UK, 2BRC Bioinformatics core, London, UK, 3King's College Hospital, London, UK

DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Worley*1,2, A. Almoudaris1,2, P. Bassett3,4, J. Segal1,2, A. Akbar2,4, P. Aylin5, O. Faiz1,2

1St Mark's Hospital and Academic Institute, Surgical Epidemiology Trials and Outcome Centre, London, UK, 2Imperial College London, Department of Surgery and Cancer, London, UK, 3Statsconsultancy Ltd., Buckinghamshire, UK, 4St Mark's Hospital and Academic Institute, London, UK, 5Imperial College London, Dr Foster Unit, Department of Primary Care and Public Health, London, UK

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()